LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
March 20, 2024 07:00 ET
|
LAVA Therapeutics N.V.
LAVA-1207 progressing in Phase 1/2a study, with pembrolizumab combination expected to begin in Q2 2024In March 2024, Pfizer paid LAVA $7 million for achieving a clinical milestone for...
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
March 05, 2024 07:30 ET
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, March 05, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its...
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
January 25, 2024 07:00 ET
|
LAVA Therapeutics N.V.
Collaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC Enrollment will continue in the monotherapy and IL-2 combination arms of the...
Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
November 16, 2023 07:00 ET
|
LAVA Therapeutics N.V.
LAVA-1207 in mCRPC continues Phase 1/2a dose escalation study in monotherapy arm and in combination with IL-2Seagen initiated a Phase 1 study of SGN-EGFRd2 (LAVA-1223) to evaluate the safety and...
LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023 07:11 ET
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™...
LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
August 22, 2023 07:00 ET
|
LAVA Therapeutics N.V.
Significant progress with lead program LAVA-1207 in mCRPC reaching dose level 8Significant progress with collaborators including selection of lead candidate by Janssen Biotech and IND clearance for...
LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference
August 14, 2023 07:00 ET
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA , Aug. 14, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody®...
LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway
June 14, 2023 09:00 ET
|
LAVA Therapeutics N.V.
• LAVA-1207 for the treatment of prostate cancer will continue as the lead program• LAVA-051 Phase 1/2a clinical trial will be discontinued• Associated cost savings and initiatives are expected to...
LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
June 08, 2023 07:00 ET
|
LAVA Therapeutics N.V.
Lead development candidate selected by Janssen Biotech under research collaboration provides a milestone payment to LAVAStrong balance sheet expected to provide cash runway into 2026 UTRECHT, The...
LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development
June 01, 2023 16:20 ET
|
LAVA Therapeutics N.V.
Through a research collaboration with Janssen, a lead candidate was identified for further development towards clinical studies.In May 2020, LAVA entered into a research collaboration and license...